The company maintains a vulnerable capital structure with $8.6 billion in total debt and a significant goodwill concentration of $4.2 billion, representing 32% of the total asset base as of 2026Q1.
| Total Current Assets | 4.93B | 4.35B | 4.35B | 4.51B | 3.93B | 3.76B | 3.57B | 3.96B | 3.71B |
| Cash & Short-Term Investments | 1.12B | 574M | 675M | 693M | 706M | 737M | 12M | 319M | 244M |
| Cash Only | 1.12B | 574M | 675M | 693M | 706M | 737M | 12M | 319M | 244M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 1.38B | 1.43B | 1.49B | 1.86B | 1.61B | 1.51B | 1.41B | 1.57B | 1.59B |
| Days Sales Outstanding | 86.05 | 84.14 | 84.99 | 108.22 | 94.94 | 87.54 | 78.51 | 73.83 | 59.47 |
| Inventory | 1.37B | 0 | 1.32B | 1.31B | 1B | 915M | 913M | 1.07B | 994M |
| Days Inventory Outstanding | 136.24 | - | 179.38 | 190.84 | 159.59 | 140.21 | 157.27 | 171.91 | 77.31 |
| Other Current Assets | 1.06B | 2.35B | 861M | 643M | 616M | 596M | 1.24B | 992M | 883M |
| Total Non-Current Assets | 8.06B | 8.52B | 8.75B | 7.55B | 7.02B | 6.92B | 6.54B | 6.59B | 6.78B |
| Property, Plant & Equipment | 1.28B | 0 | 1.32B | 1.36B | 1.23B | 1.2B | 1.01B | 762M | 651M |
| Fixed Asset Turnover | 6.43x | - | 4.83x | 4.62x | 5.01x | 5.24x | 6.44x | 10.21x | 15.02x |
| Goodwill | 4.15B | 4.15B | 4.68B | 4.6B | 4.6B | 4.6B | 4.6B | 4.6B | 4.6B |
| Intangible Assets | 1.1B | 1.13B | 1.41B | 533M | 649M | 651M | 503M | 569M | 812M |
| Long-Term Investments | 0 | 0 | 27M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 1.53B | 3.23B | 361M | 250M | 272M | 464M | 421M | 659M | 714M |
| Total Assets | 13B | 12.87B | 13.1B | 12.06B | 10.96B | 10.68B | 10.11B | 10.55B | 10.49B |
| Asset Turnover | 0.47x | 0.48x | 0.49x | 0.52x | 0.56x | 0.59x | 0.65x | 0.74x | 0.93x |
| Asset Growth % | 14.35% | -1.79% | 8.65% | 10.07% | 2.57% | 5.66% | -4.16% | 0.51% | - |
| Total Current Liabilities | 2.5B | 2.39B | 2.72B | 2.92B | 2.51B | 2.6B | 2.67B | 1.34B | 1.54B |
| Accounts Payable | 983M | 952M | 1.15B | 1.31B | 1.13B | 1.38B | 259M | 258M | 289M |
| Days Payables Outstanding | 128.7 | 121.75 | 156.56 | 190.7 | 180.11 | 211.77 | 44.61 | 41.41 | 22.48 |
| Short-Term Debt | 16M | 56M | 64M | 55M | 57M | 55M | 8M | 48M | 115M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 322M |
| Other Current Liabilities | 1.5B | 1.3B | 1.37B | 1.34B | 1.14B | 975M | 2.12B | 793M | 6M |
| Current Ratio | 1.97x | 1.82x | 1.60x | 1.54x | 1.56x | 1.45x | 1.33x | 2.95x | 2.40x |
| Quick Ratio | 1.42x | 1.82x | 1.11x | 1.09x | 1.17x | 1.10x | 0.99x | 2.15x | 1.76x |
| Cash Conversion Cycle | 93.6 | - | 107.81 | 108.37 | 74.42 | 15.98 | 191.16 | 204.32 | 114.3 |
| Total Non-Current Liabilities | 9.59B | 9.72B | 9.91B | 9.21B | 9.34B | 9.59B | 1.95B | 2.17B | 2.6B |
| Long-Term Debt | 8.55B | 8.64B | 8.86B | 8.75B | 8.9B | 9.13B | 0 | 70M | 34M |
| Capital Lease Obligations | 116M | 116M | 112M | 125M | 150M | 184M | 23M | 68M | 0 |
| Deferred Tax Liabilities | 244M | 57M | 74M | 47M | 19M | 4M | 128M | 139M | 149M |
| Other Non-Current Liabilities | 984M | 924M | 865M | 287M | 261M | 279M | 1.8B | 1.9B | 2.57B |
| Total Liabilities | 12.09B | 12.12B | 12.63B | 12.13B | 11.85B | 12.19B | 4.62B | 3.51B | 4.15B |
| Total Debt | 8.57B | 8.8B | 9.04B | 8.93B | 9.11B | 9.36B | 31M | 186M | 149M |
| Net Debt | 7.45B | 8.23B | 8.36B | 8.24B | 8.41B | 8.63B | 19M | -133M | -95M |
| Debt / Equity | 9.49x | 11.70x | 19.14x | - | - | - | 0.01x | 0.03x | 0.02x |
| Debt / EBITDA | 5.56x | 5.37x | 5.13x | 5.71x | 4.75x | 4.44x | 0.01x | 0.04x | 0.03x |
| Net Debt / EBITDA | 4.84x | 5.02x | 4.74x | 5.27x | 4.38x | 4.09x | 0.01x | -0.03x | -0.02x |
| Interest Coverage | 1.97x | 1.84x | 2.55x | 2.28x | 3.66x | 6.93x | 474.50x | 593.50x | - |
| Total Equity | 903M | 752M | 472M | -70M | -892M | -1.51B | 5.49B | 7.04B | 6.35B |
| Equity Growth % | 618.73% | 59.32% | 774.29% | 92.15% | 40.85% | -127.49% | -22.02% | 10.82% | - |
| Book Value per Share | 3.43 | 2.88 | 1.82 | -0.27 | -3.50 | -5.95 | 21.64 | 27.79 | 25.08 |
| Total Shareholders' Equity | 903M | 752M | 472M | -70M | -892M | -1.51B | 5.49B | 7.04B | 6.35B |
| Common Stock | 3M | 3M | 3M | 3M | 3M | 3M | 6.11B | 7.95B | 7.26B |
| Retained Earnings | 1.25B | 1.11B | 1.01B | 443M | -331M | -998M | 0 | 0 | 0 |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -539M | -527M | -649M | -541M | -564M | -513M | -622M | -914M | -908M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
High Debt Service Burden
According to the most recent quarterly financial data, Organon's equity base has shown extreme volatility, fluctuating from a deficit of $70 million in 2023Q4 to a modest $903 million by 2026Q1, underscoring the persistent fragility of the company's capital structure amidst ongoing operational headwinds.
The erratic movement in equity suggests that the company's net income generation is insufficient to consistently build book value, leaving the balance sheet highly sensitive to any impairment or non-operating charge. Investors should monitor whether this trend of thin capitalization persists, as it limits the company's financial flexibility during periods of market volatility.
Based on reported figures, Organon maintains a significant debt load of $8.6 billion as of 2026Q1, with the debt-to-equity ratio reaching as high as 181.54 in 2024Q1, which indicates that the company's capital structure is heavily reliant on external financing rather than internal equity accumulation.
The high leverage ratio suggests that a substantial portion of the company's operating cash flow is likely diverted toward interest obligations, potentially starving the business of necessary R&D investment. This reliance on debt warrants further investigation into the maturity profile and the company's ability to refinance under potentially less favorable credit conditions.
As reported in financial statements, goodwill accounts for approximately $4.2 billion of the $13.0 billion total asset base in 2026Q1, representing a significant portion of the company's valuation that is inherently subjective and susceptible to future impairment charges if segment performance continues to decline.
The heavy reliance on intangible assets suggests that the company's tangible asset base is relatively small, which may limit the collateral available for future financing needs. Analysts should consider the risk that these intangible assets may not provide the expected long-term economic benefits if the legacy brand portfolio faces accelerated competitive erosion.
Based on the latest quarterly filings, Organon's cash position of $1.1 billion in 2026Q1, combined with a current ratio of 1.97, suggests a temporary improvement in short-term liquidity compared to the 1.54 ratio observed in 2023Q4, providing a limited buffer against immediate operational shocks.
While the current ratio appears to have stabilized, the absolute cash balance remains small relative to the company's total debt obligations. This liquidity profile suggests that the company may struggle to maintain its current pace of acquisitions and debt service if working capital requirements become more demanding in the coming quarters.
Quick answers to the most common questions about buying OGN stock.
As of 2025, Organon & Co. (OGN) had total assets of $12.87B including $4.35B in current assets.
Organon & Co. (OGN) carries total debt of $8.80B, offset by $574.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Organon & Co. (OGN) has total shareholders' equity (book value) of $752.0M ($2.88 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Organon & Co. (OGN) reported a current ratio of 1.82x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.